NO20024291D0 - Ny anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3- pyridylmetylaminometyl]kroman og dets fysiologisk akseptablesalter - Google Patents

Ny anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3- pyridylmetylaminometyl]kroman og dets fysiologisk akseptablesalter

Info

Publication number
NO20024291D0
NO20024291D0 NO20024291A NO20024291A NO20024291D0 NO 20024291 D0 NO20024291 D0 NO 20024291D0 NO 20024291 A NO20024291 A NO 20024291A NO 20024291 A NO20024291 A NO 20024291A NO 20024291 D0 NO20024291 D0 NO 20024291D0
Authority
NO
Norway
Prior art keywords
pyridylmethylaminomethyl
fluorophenyl
physiologically acceptable
chroman
acceptable salts
Prior art date
Application number
NO20024291A
Other languages
English (en)
Other versions
NO329583B1 (no
NO20024291L (no
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Frank Weber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20024291L publication Critical patent/NO20024291L/no
Publication of NO20024291D0 publication Critical patent/NO20024291D0/no
Publication of NO329583B1 publication Critical patent/NO329583B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024291A 2000-03-10 2002-09-09 Anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3-pyridylmetylaminometyl]kroman og dets fysiologisk akseptable salter til fremstilling av medikamenter, samt farmasoytiske preparater som omfatter forbindelsene og minst ett legemiddel mot Parkinsonssykdom NO329583B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00104531 2000-03-10
PCT/EP2001/001038 WO2001068063A2 (en) 2000-03-10 2001-02-01 Novel use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Publications (3)

Publication Number Publication Date
NO20024291L NO20024291L (no) 2002-09-09
NO20024291D0 true NO20024291D0 (no) 2002-09-09
NO329583B1 NO329583B1 (no) 2010-11-15

Family

ID=8168017

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024291A NO329583B1 (no) 2000-03-10 2002-09-09 Anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3-pyridylmetylaminometyl]kroman og dets fysiologisk akseptable salter til fremstilling av medikamenter, samt farmasoytiske preparater som omfatter forbindelsene og minst ett legemiddel mot Parkinsonssykdom

Country Status (29)

Country Link
US (1) US7928128B2 (no)
EP (2) EP1299099B1 (no)
JP (1) JP4901046B2 (no)
KR (1) KR100830139B1 (no)
CN (1) CN1188123C (no)
AR (1) AR033807A1 (no)
AT (1) ATE307578T1 (no)
AU (2) AU3022201A (no)
BR (1) BR0109119A (no)
CA (1) CA2402402C (no)
CO (1) CO5271686A1 (no)
CZ (1) CZ301807B6 (no)
DE (1) DE60114419T2 (no)
DK (1) DK1299099T3 (no)
ES (1) ES2251460T3 (no)
HK (1) HK1054198B (no)
HU (1) HU229309B1 (no)
ME (1) MEP5608A (no)
MX (1) MXPA02008800A (no)
MY (1) MY136976A (no)
NO (1) NO329583B1 (no)
PL (1) PL200781B1 (no)
RS (1) RS51316B (no)
RU (1) RU2278663C2 (no)
SI (1) SI1299099T1 (no)
SK (1) SK286933B6 (no)
UA (1) UA73981C2 (no)
WO (1) WO2001068063A2 (no)
ZA (1) ZA200208133B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit
JP2004538289A (ja) * 2001-07-26 2004-12-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ２−［５−（４−フルオロフェニル）−３−ピリジルメチルアミノメチル］−クロマンおよびその生理学的に許容し得る塩の新規な使用
PL208787B1 (pl) * 2001-09-19 2011-06-30 Merck Patent Gmbh (2R, 4R/S)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol i (2R, 4R)-2-({[5-(4-fluorofenylo)-pirydyn-3ylmetylo)]-amino}-metylo)-chroman-4-ol, sposoby ich otrzymywania i zastosowanie do wytwarzania preparatów medycznych oraz zawierająca je kompozycja farmaceutyczna
MX2007015359A (es) * 2005-06-21 2008-02-15 Merck Patent Gmbh Preparacion farmaceutica solida que contiene (r)-(-)-2-[5-(4- fluorofenil)-3-piridilmetilaminometil]-cromano.
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US10010515B2 (en) 2011-03-01 2018-07-03 Pharnext Therapeutic approaches for treating Parkinson's disease
CN108937972A (zh) * 2018-06-08 2018-12-07 青岛大学附属医院 一种多特征融合的就诊用户情绪监控方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) * 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69123090D1 (de) * 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) * 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
AU3929493A (en) 1992-03-11 1993-10-05 Interneuron Pharmaceuticals, Inc. Reducing post-prandial fluctuations in plasma concentrations of large neutral amino acids (lnaa)
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
JPH08503448A (ja) * 1992-12-07 1996-04-16 メレルダウファーマス−ティカルズ インコーポレイテッド ５ｈｔ▲下１▼▲ａ▼受容体アゴニストによる不随意運動の処置
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
WO1995014006A1 (en) * 1993-11-19 1995-05-26 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations OCTAHYDROBENZO[f]QUINOLINE-BASED RECEPTOR AGONISTS AND ANTAGONISTS
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
FR2723091B1 (fr) * 1994-07-29 1996-11-08 Esteve Labor Dr Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles
SI0707007T1 (en) * 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
US5502080A (en) * 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
AU6517196A (en) * 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
US5670667A (en) * 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) * 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) * 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
ATE253058T1 (de) * 1997-09-02 2003-11-15 Duphar Int Res Piperidin- und piperazin derivate als 5-ht1- rezeptor-agonisten
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
EP1061924A1 (en) 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
CZ20003355A3 (cs) * 1998-03-17 2002-05-15 Pfizer Products Inc. Bicyklo[2,2,1]heptany a příbuzné sloučeniny, farmaceutické kompozice a způsoby léčení na jejich bázi
FR2781671A1 (fr) * 1998-07-28 2000-02-04 Synthelabo Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
NO329583B1 (no) 2010-11-15
CO5271686A1 (es) 2003-04-30
ES2251460T3 (es) 2006-05-01
HK1054198A1 (en) 2003-11-21
DE60114419T2 (de) 2006-07-27
CA2402402C (en) 2013-01-22
SK12642002A3 (sk) 2003-02-04
EP1645273A3 (en) 2006-04-19
RS51316B (sr) 2010-12-31
SK286933B6 (sk) 2009-07-06
NO20024291L (no) 2002-09-09
PL356428A1 (en) 2004-06-28
US7928128B2 (en) 2011-04-19
MY136976A (en) 2008-12-31
WO2001068063A3 (en) 2002-05-10
MXPA02008800A (es) 2003-02-12
CZ20022951A3 (cs) 2003-01-15
DE60114419D1 (de) 2005-12-01
EP1299099B1 (en) 2005-10-26
MEP5608A (xx) 2010-02-10
EP1645273A2 (en) 2006-04-12
HU229309B1 (en) 2013-10-28
UA73981C2 (en) 2005-10-17
SI1299099T1 (sl) 2006-04-30
AU2001230222C1 (en) 2005-09-22
CN1188123C (zh) 2005-02-09
BR0109119A (pt) 2003-06-03
HK1054198B (zh) 2005-05-20
PL200781B1 (pl) 2009-02-27
RU2002127006A (ru) 2004-03-27
HUP0300079A2 (en) 2003-05-28
US20030181486A1 (en) 2003-09-25
KR20030016236A (ko) 2003-02-26
JP2004522692A (ja) 2004-07-29
ATE307578T1 (de) 2005-11-15
CA2402402A1 (en) 2001-09-20
AU3022201A (en) 2001-09-24
ZA200208133B (en) 2004-04-01
EP1299099A2 (en) 2003-04-09
CZ301807B6 (cs) 2010-06-30
YU67402A (sh) 2006-01-16
JP4901046B2 (ja) 2012-03-21
WO2001068063A2 (en) 2001-09-20
AR033807A1 (es) 2004-01-07
KR100830139B1 (ko) 2008-05-20
AU2001230222B2 (en) 2005-03-17
CN1416344A (zh) 2003-05-07
RU2278663C2 (ru) 2006-06-27
DK1299099T3 (da) 2006-03-06

Similar Documents

Publication Publication Date Title
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
UA74337C2 (uk) Застосування 1-[4-(5-ціаноіндол-3-іл)бутил]-4-(2-карбамоїлбензофуран-5-іл)-піперазину для лікування біполярних розладів та манії
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
WO2003015779A3 (de) Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
NO20024291D0 (no) Ny anvendelse av (R)-(-)-2[5-(4-fluorfenyl)-3- pyridylmetylaminometyl]kroman og dets fysiologisk akseptablesalter
ATE410148T1 (de) Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
NZ535611A (en) Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
BR0009080A (pt) Método de tratamento da apnéia do sono
DE60213234D1 (de) 4-(penylpiperidin-4-ylidenmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen, angstzuständen oder erkrankungen des magen-darm-trakts
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
HUP0102507A2 (hu) Paroxetin alkalmazása a dohányzás abbahagyásának elősegítésére, illetve a visszaeső dohányzás csökkentésére vagy megelőzésére szolgáló gyógyszerkészítmények előállítására
ATE228126T1 (de) 2- 4-(4-(4,5-dichlor-2-methylimidazol-1- yl)butyl)piperazin-1-yl -5-fluorpyrimidin, seine herstellung und therapeutische verwendung
NO20010984L (no) Anvendelse av R(+)-<alfa>-(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etyl]-4-piperidinmetanol for behandling av sovnforstyrrelser
SE9802119D0 (sv) New use
BR0115297A (pt) Usos de antagonistas seletivos do receptor de dopamina d2 e agonistas do receptor 5-ht1a combinados
FR2804867B1 (fr) Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees